Table 3 Characteristics of patients divided by HSP47 expression in cancer cells or number of HSP47-positive fibroblasts in patients with lung cancer

N, no

67

50.4%

66

49.6%

91

68.4%

42

31.6%

Age, median

69

(61.0–77.0)

[67]

74

(63.0–77.0)

[66]

p = 0.341

71

(63.0–77.0)

[91]

68.5

(61.0–77.0)

[42]

p = 0.673

Sex Male, no

41

61.2%

[67]

46

69.7%

[66]

p = 0.363

68

74.7%

[91]

19

45.2%

[42]

p = 0.015*

BMI (kg/m²), median

22.8

(20.9–25.0)

[67]

22.8

(20.8–24.5)

[66]

p = 0.968

22.9

(21.5–25.0)

[91]

21.9

(20.7–24.0)

[42]

p = 0.263

History of smoking, no

30

48.4%

[62]

17

27.9%

[61]

p = 0.026*

61

71.8%

[85]

15

39.5%

[38]

p = 0.012*

Brinkman index, median

877.5

(455–1515)

[30]

900

(562–1200)

[17]

p = 0.322

900

(680–1500)

[61]

620

(275–1125)

[15]

p = 0.042*

 %VC, median (%)

111.4

(102.3–120.4)

[53]

109

(98.2–122.3)

[50]

p = 0.611

106.4

(94.0–120.1)

[68]

115

(104.1–123.2)

[35]

p = 0.041*

 FEV1/FVC, median (%)

73.9

(64.4–80.3)

[53]

73.4

(66.8–77.0)

[50]

p = 0.559

73.5

(64.8–79.0)

[68]

74.6

(64.5–77.4)

[35]

p = 0.983

 %DLCO, median (%)

97.6

(82.1–109.9)

[50]

80.9

(65.0–97.1)

[48]

p = 0.001*

84.3

(73.4–104.3)

[65]

93.4

(77.0–109.1)

[33]

p = 0.371

KL-6, median (U/mL)

193

(152.0–303.5)

[37]

263

(178–370.3)

[44]

p = 0.020*

247

(171–345.5)

[56]

231

(167.5–316.5)

[16]

p = 0.377

Adenocarcinoma, no

60

89.6%

[67]

39

59.1%

[66]

p < 0.001*

57

62.6%

[91]

42

100.0%

[42]

p < 0.001*

pT classification, no (T3, T4)

2

3.0%

[67]

6

9.1%

[66]

p = 0.165

8

8.8%

[91]

0

0.0%

[42]

p = 0.557

pN classification, no (N1, N2)

8

11.9%

[67]

15

22.7%

[66]

p = 0.114

21

23.1%

[91]

2

4.8%

[42]

p = 0.012*

pM classification, no (M1)

1

1.5%

[67]

1

1.5%

[66]

p = 1.000

2

2.2%

[91]

0

0.0%

[42]

p = 1.000

pStage

p = 0.125

p = 0.025*

 I

56

83.6%

[67]

44

66.7%

[66]

62

68.1%

[91]

38

90.5%

[42]

 II

7

10.5%

[67]

12

18.2%

[66]

15

16.5%

[91]

4

9.5%

[42]

 III

3

4.5%

[67]

9

13.7%

[66]

12

13.2%

[91]

0

0.0%

[42]

 IV

1

1.5%

[67]

1

1.5%

[66]

2

2.2%

[91]

0

0.0%

[42]

Recurrence, no

13

19.4%

[67]

16

24.2%

[66]

p = 0.535

27

29.7%

[91]

2

4.8%

[42]

p = 0.001*

Primary disease death, no

12

17.9%

[67]

7

10.6%

[66]

p = 0.3221

15

16.5%

[91]

3

7.1%

[42]

p = 0.173

HSP47 expression positive in cancer cells, no

–

–

–

–

39

42.9%

[91]

28

66.7%

[42]

p = 0.015*

HSP47-positive fibroblasts, no

71.0

(28.5–117.5)

[67]

125

(74.1–180.6)

[66]

p < 0.001*

–

–

–

–